Xeris Biopharma Holdings Inc (XERS) concluded trading on Wednesday at a closing price of $5.71, with 4.63 million shares of worth about $26.44 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 106.88% during that period and on March 26, 2025 the price saw a loss of about -2.73%. Currently the company’s common shares owned by public are about 149.43M shares, out of which, 142.00M shares are available for trading.
Stock saw a price change of 3.63% in past 5 days and over the past one month there was a price change of 56.01%. Year-to-date (YTD), XERS shares are showing a performance of 68.44% which increased to 171.90% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.69 but also hit the highest price of $5.97 during that period. The average intraday trading volume for Xeris Biopharma Holdings Inc shares is 2.40 million. The stock is currently trading 20.78% above its 20-day simple moving average (SMA20), while that difference is up 41.69% for SMA50 and it goes to 81.63% higher than SMA200.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) currently have 149.43M outstanding shares and institutions hold larger chunk of about 42.76% of that.
The stock has a current market capitalization of $879.00M and its 3Y-monthly beta is at 1.16. It has posted earnings per share of -$0.38 in the same period. It has Quick Ratio of 1.19. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for XERS, volatility over the week remained 6.15% while standing at 6.80% over the month.
Stock’s fiscal year EPS is expected to rise by 83.57% while it is estimated to increase by 299.45% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on November 11, 2024 offering a Neutral rating for the stock and assigned a target price of $3 to it. Coverage by Oppenheimer stated Xeris Biopharma Holdings Inc (XERS) stock as an Outperform in their note to investors on March 28, 2024, suggesting a price target of $5 for the stock. On August 28, 2023, Craig Hallum Initiated their recommendations, while on October 21, 2022, Jefferies Initiated their ratings for the stock with a price target of $4. Stock get a Buy rating from Craig Hallum on April 28, 2022.
